Explainable artificial intelligence of DNA methylation-based brain tumor diagnostics.

Journal: Nature communications
PMID:

Abstract

We have recently developed a machine learning classifier that enables fast, accurate, and affordable classification of brain tumors based on genome-wide DNA methylation profiles that is widely employed in the clinic. Neuro-oncology research would benefit greatly from understanding the underlying artificial intelligence decision process, which currently remains unclear. Here, we describe an interpretable framework to explain the classifier's decisions. We show that functional genomic regions of various sizes are predominantly employed to distinguish between different tumor classes, ranging from enhancers and CpG islands to large-scale heterochromatic domains. We detect a high degree of genomic redundancy, with many genes distinguishing individual tumor classes, explaining the robustness of the classifier and revealing potential targets for further therapeutic investigation. We anticipate that our resource will build up trust in machine learning in clinical settings, foster biomarker discovery and development of compact point-of-care assays, and enable further epigenome research of brain tumors. Our interpretable framework is accessible to the research community via an interactive web application ( https://hovestadtlab.shinyapps.io/shinyMNP/ ).

Authors

  • Salvatore Benfatto
    BioMed X Institute (GmbH), Im Neuenheimer Feld 583, 69120, Heidelberg, Germany.
  • Martin Sill
    Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. m.sill@kitz-heidelberg.de.
  • David T W Jones
    Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Stefan M Pfister
    Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Felix Sahm
    Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Andreas von Deimling
    Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • David Capper
    German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), 69210 Heidelberg, Germany. frederick.klauschen@charite.de david.capper@charite.de.
  • Volker Hovestadt
    Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.